| 摘要 |
PURPOSE:To obtain a stable water-based liquid agent having improved solubility of principal drug component, by compounding an antiallergic compound which is a selective inhibitor of 5-lipoxygenase with alpha-cyclodextrin and/or dimethyl-beta- cyclodextrin. CONSTITUTION:The objective liquid agent is produced by compounding the compound of formula with at least one kind of compound selected from alpha- cyclodextrin and dimethyl-beta-cyclodextrin. The compound of formula is a selective inhibitor of 5-lipoxygenase which is one of important metabolic enzymes of arachidonic acid cascade and effective in suppressing allergic asthma caused by IgE because of its activity to suppress the formation of SRS-A and LTB4. The application of the agent as a collunarium or ophthalmic solution has been difficult because of its poor solubility. The solubility can be increased by the addition of alpha-cyclodextrin and/or dimethyl-beta-cyclodextrin (usually at an amount of 0.1-15w/v%).
|
